The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects

2.

Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy

3.

Poor agreement between diagnostic tests for breast cancer-related lymphedema

4.

Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain

5.

EU Adds CAR-T Warning; New Blincyto Indication; Good News in Pancreatic Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot